DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
6 editorial guides covering the most common moves between Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda. Dose mapping, washout, and the verdict on whether the switch is worth the friction.
For most weight-loss patients who started on Ozempic for cost or supply reasons, switching to Wegovy is administratively cleaner and clinically equivalent at matched doses. The real upside is access to the 2.4 mg ceiling, which contributes most of the additional weight loss in trials.
Wegovy-to-Zepbound is the most-asked switch in our editorial queue, driven by the SURMOUNT-5 readout. The data supports switching for plateau patients, but the titration restart is non-trivial. Move only if Wegovy genuinely stalled, not because Zepbound polled better.
For T2D patients who plateau on Ozempic, Mounjaro is the most evidence-backed next step. The mechanism difference (GIP + GLP-1) genuinely matters here, unlike most class switches. SURPASS-2 head-to-head data justifies the change.
The Mounjaro-to-Zepbound switch is administrative reality, not clinical change. We see it most in patients who got Mounjaro off-label during the 2024-2025 supply easing, then needed to formalize coverage. Cash-pay shift is the meaningful gain.
Saxenda-to-Wegovy is one of the cleanest switches in the class. Lower injection burden, better efficacy, similar insurance treatment. The case to stay on Saxenda is small.
For weight-loss-focused patients who never had a diabetes diagnosis, Ozempic-to-Zepbound is the logical 2026 destination. You get on-label coverage, a better evidence profile, and the cheapest cash-pay channel in one move. The cost of the switch is restarting titration.
Editorial summaries, not medical advice. Always coordinate switches with your prescriber. Dose conversions reflect typical practice and may differ in your case.